Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.66 |
| ▸ | ABL1 | P00519 | 8/20 | 0.42 |
| ▸ | CTSD | P07339 | 4/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826113 | 1.00 | BACE1 (0.66) | BACE1ABL1CTSDBACE2REN | |
| SCHEMBL15839628 | 0.87 | BACE1 (0.78) | BACE1CTSDBACE2 | |
| SCHEMBL17260359 | 0.87 | BACE1 (0.78) | BACE1CTSDBACE2 | |
| SCHEMBL17264645 | 0.86 | BACE1 (0.70) | BACE1 | |
| SCHEMBL15825543 | 0.86 | BACE1 (0.70) | BACE1 | |
| SCHEMBL15839677 | 0.85 | BACE1 (0.72) | BACE1 | |
| SCHEMBL17260317 | 0.85 | BACE1 (0.72) | BACE1 | |
| SCHEMBL15839629 | 0.83 | BACE1 (0.70) | BACE1 | |
| SCHEMBL17260376 | 0.82 | ABL1 (0.44) | BACE1ABL1CTSDBACE2REN | |
| SCHEMBL17260341 | 0.81 | BACE1 (0.66) | BACE1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935256-B1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BACE1, APP, BACE2 | BACE1 1/4885ABL1 2222/4885CTSD 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.